I wrote earlier today about how I now regarded Phorm (PHRM) as more of a sell than a buy. Following extensive conversations with a number of folks I now have it officially “in sights.”
Previous companies to be accorded that honour were – until they were forced to changed management - Sefton (SER) and Vialogy (VIY). We all know what happened there.
My target price for this company – now trading at 13.5p – valuing the enterprise at a preposterous £65 million – is buttons. More to follow….